<DOC>
	<DOCNO>NCT00889343</DOCNO>
	<brief_summary>The purpose study determine whether sorafenib combination chemotherapy positive effect time progression tumor death treatment large bowel cancer already progress first chemotherapy .</brief_summary>
	<brief_title>Study Evaluate Effects Sorafenib Combined With Chemotherapy ( FOLFOX6 FOLFIRI ) Second-Line Treatment Colorectal Cancer</brief_title>
	<detailed_description>Patients metastatic CRC receive first-line therapy Oxaliplatin- Irinotecan base Fluoropyrimidine contain regimen ± bevacizumab progression subsequently , eligible study . Patients randomize receive chemotherapy ( FOLFOX6 FOLFIRI ) + sorafenib 400 mg bid chemotherapy + placebo . Patients receive Oxaliplatin base Fluoropyrimidine contain regimen first-line obtain FOLFIRI study . Patients receive Irinotecan base Fluoropyrimidine contain regimen first-line obtain FOLFOX6 . Primary objective study compare Progression-free-survival ( PFS ) patient receive chemotherapy ( FOLFOX6 FOLFIRI ) + sorafenib chemotherapy + placebo .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age &gt; 18 year . ECOG Performance Status 0 2 Life expectancy least 12 week . Subjects least one unidimensional ( RECIST ) measurable lesion metastatic colorectal carcinoma firstline chemotherapy Oxaliplatin Irinotecan base Fluoropyrimidine contain regimen ± bevacizumab progression subsequently . Lesions must measure CTscan MRI . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count 100,000/μl Total bilirubin &lt; 1.5 time upper limit normal ALT AST &lt; 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) Alkaline phosphatase &lt; 4 x upper limit normal PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . ] Serum creatinine &lt; 1.5 x upper limit normal Signed date informed consent start specific protocol procedure History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 mo prior study entry allow ) ; cardiac arrythmias require antiarrythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension History HIV infection chronic hepatitis B C Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) Patients seizure disorder require medication ( steroids antiepileptic ) History organ allograft Patients evidence history bleed diathesis Patients undergoing renal dialysis Known deficit Dihydropyrimidine Deshydrogenase ( DPD ) Contraindications use atropine patient receive FOLFIRI Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry . Peripheral sensory neuropathy &gt; CTC grade 2 Chronic inflammatory bowel disease ; ileus ; genetic fructose intolerance Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Fertile woman men ( &lt; 2 year last menstruation woman ) must use effective mean contraception ( intrauterine contraceptive device , contraceptive implant , injectables ( hormonal depot ) , transdermal hormonal contraception ( contraceptive patch ) , sexual abstinence vasectomise partner ) treatment least 6 month last administration medication . Substance abuse , medical , psychological social condition may interfere patient‟s participation study evaluation study result Any condition unstable could jeopardize safety patient compliance study 18 . Patients unable swallow oral medication . Any anticancer chemotherapy immunotherapy study within 4 week study entry . Radiotherapy study within 3 week start study drug . ( Palliative radiotherapy allow ) . Major surgery within 4 week start study Autologous bone marrow transplant stem cell rescue within 4 month prior study treatment Use biologic response modifier , GCSF , within 3 week study entry . [ GCSF hematopoietic growth factor may use management acute toxicity febrile neutropenia clinically indicate discretion investigator , however , may substitute require dose reduction . ] [ Patients take chronic erythropoietin permit provide dose adjustment undertaken within 2 month prior study study ] Investigational drug therapy outside trial within 4 week study entry Prior exposure study drug . Any St. John´s wort contain remedy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Second-line therapy metastatic colorectal cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>palliative therapy</keyword>
	<keyword>progression firstline therapy Oxaliplatin- Irinotecan base Fluoropyrimidine contain regimen ± bevacizumab</keyword>
</DOC>